הלוואות ואשראי לטווח ארוך של החברה: Akebia (AKBA)

The price action of Akebia Therapeutics (AKBA), which specializes in renal pathology therapies, demonstrates long-term debt at 0.16. Stringent FDA requirements and patent protection create significant barriers to entry for new players, strengthening the issuer's position. Business stability is ensured by the constant demand for dialysis, rendering the asset insensitive to market downturns, while geopolitical tensions only create risks for raw material logistics and foreign certification.

This indicator aggregates obligations with maturities exceeding one year, measuring the long-term financial burden and the issuer's ability to service capital loans. Amid geopolitical disruptions and logistics failures regarding component supplies for Akebia Therapeutics (AKBA) drugs, the company's long-term debt level serves as a marker of business resilience against delays in drug certification and clinical trials.